Synold TW - Search Results

1

Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity.

Synold TW, Newman EM, Carroll M, Muggia FM, Groshen S, Johnson K, Doroshow JH. Synold TW, et al. Clin Cancer Res. 1998 Oct;4(10):2349-55. Clin Cancer Res. 1998. PMID: 9796964

2

Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion.

Synold TW, Doroshow JH. Synold TW, et al. J Infus Chemother. 1996 Spring;6(2):69-73. J Infus Chemother. 1996. PMID: 8809652 Review.

3

Failure of pretreatment with intravenous folic acid to alter the cumulative hematologic toxicity of lometrexol.

Muggia FM, Synold TW, Newman EM, Jeffers S, Leichman LP, Doroshow JH, Johnson K, Groshen S. Muggia FM, et al. Among authors: synold tw. J Natl Cancer Inst. 1996 Oct 16;88(20):1495-6. doi: 10.1093/jnci/88.20.1495. J Natl Cancer Inst. 1996. PMID: 8841028 Clinical Trial. No abstract available.

4

Simple and sensitive method for the quantitative analysis of lometrexol in plasma using high-performance liquid chromatography with electrochemical detection.

Synold TW, Xi B, Newman EM, Muggia FM, Doroshow JH. Synold TW, et al. J Chromatogr B Biomed Appl. 1996 Aug 30;683(2):245-9. doi: 10.1016/0378-4347(96)00122-3. J Chromatogr B Biomed Appl. 1996. PMID: 8891922

5

Role of folylpolygutamate synthetase (FPGS) in antifolate chemotherapy; a biochemical and clinical update.

Synold TW, Willits EM, Barredo JC. Synold TW, et al. Leuk Lymphoma. 1996 Mar;21(1-2):9-15. doi: 10.3109/10428199609067573. Leuk Lymphoma. 1996. PMID: 8907263 Review.

6

Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor.

Synold TW, Tetef ML, Doroshow JH. Synold TW, et al. Semin Oncol. 1998 Aug;25(4 Suppl 10):93-9. Semin Oncol. 1998. PMID: 9768830 Clinical Trial.

7

High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically.

Lara PN Jr, Gandara DR, Wurz GT, Lau D, Uhrich M, Turrell C, Raschko J, Edelman MJ, Synold T, Doroshow J, Muggia F, Perez EA, DeGregorio M. Lara PN Jr, et al. Cancer Chemother Pharmacol. 1998;42(6):504-8. doi: 10.1007/s002800050852. Cancer Chemother Pharmacol. 1998. PMID: 9788578 Clinical Trial.

8

Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.

McLeod HL, Cassidy J, Powrie RH, Priest DG, Zorbas MA, Synold TW, Shibata S, Spicer D, Bissett D, Pithavala YK, Collier MA, Paradiso LJ, Roberts JD. McLeod HL, et al. Among authors: synold tw. Clin Cancer Res. 2000 Jul;6(7):2677-84. Clin Cancer Res. 2000. PMID: 10914709 Clinical Trial.

9

A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.

Raschko JW, Synold TW, Chow W, Coluzzi P, Hamasaki V, Leong LA, Margolin KA, Morgan RJ, Shibata SI, Somlo G, Tetef ML, Yen Y, ter Veer A, Doroshow JH. Raschko JW, et al. Among authors: synold tw. Cancer Chemother Pharmacol. 2000;46(5):403-10. doi: 10.1007/s002800000142. Cancer Chemother Pharmacol. 2000. PMID: 11127945 Clinical Trial.

10

Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin.

Doroshow JH, Synold TW, Somlo G, Akman SA, Gajewski E. Doroshow JH, et al. Among authors: synold tw. Blood. 2001 May 1;97(9):2839-45. doi: 10.1182/blood.v97.9.2839. Blood. 2001. PMID: 11313279 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

144 results

Search Page

Filters